TICKERNERD
Menu
EWTXEWTXHealthcare · Biotechnology

EWTX Stock Forecast: Edgewise Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$39
−1.70% on the day

The 14 Wall Street analysts covering Edgewise Therapeutics, Inc. hold a median 12-month price target of $53 — +34.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 24 Oct 2026 — in the upper half.

Market cap
$4.3B
Ticker Nerd rank
56/ 100
Median analyst target
$53
Analysts covering
14
Revenue$0.0
Operating income−$61.9M
Net income−$57.3M
Free cash flow−$42.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.7%
1M
−4.2%
YTD
+58.4%
1Y
+160.3%
From 52W high
−18.7%
From 52W low
+160.3%
$15
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EWTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Edgewise Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
56/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Value
83
Accruals
75
Quality
51
Issuance
47
Volatility
46
Revisions
45
Growth
31
Size
25

Momentum (86): The shares have been drifting up relative to others.

Growth (31): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EWTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EWTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26EWTXHigh $66Median $53Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $36Median $53High $66

The green dot is the last close — the median target sits +34.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Oct 2026William BlairInitiatesOutperform—
21 Sept 2026HC Wainwright & Co.MaintainsBuy$45 → $57
21 Sept 2026HC Wainwright & Co.MaintainsBuy—
20 Aug 2026JP MorganMaintainsOverweight—
20 Aug 2026JP MorganMaintainsOverweight$53 → $60
11 Aug 2026Goldman SachsMaintainsNeutral$32 → $36
11 Aug 2026Goldman SachsMaintainsNeutral—
20 July 2026Evercore ISI GroupMaintainsOutperform—
20 July 2026Evercore ISI GroupMaintainsOutperform$45 → $55
9 July 2026OppenheimerInitiatesOutperform—
9 July 2026OppenheimerInitiatesOutperform$51
6 July 2026GuggenheimMaintainsBuy$41 → $51
6 July 2026GuggenheimMaintainsBuy—
17 June 2026Goldman SachsMaintainsNeutral—
17 June 2026RBC CapitalMaintainsOutperform—
16 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.MaintainsBuy—
2 June 2026RBC CapitalMaintainsOutperform—
2 June 2026WedbushMaintainsOutperform—
17 Mar 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EWTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

EWTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Edgewise Therapeutics, Inc. returned +160.3% against +14.3% for the S&P 500, dividends included.

EWTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26EWTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EWTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
5
Fundamentals

Edgewise Therapeutics, Inc. (EWTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−24.1×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
9.5×

Cheaper than 9% of US stocks

EV / EBITDA
−17.6×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.0%

Higher than 25% of US stocks

Return on assets
−25.0%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Edgewise Therapeutics, Inc. (EWTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Edgewise Therapeutics, Inc. has a market value of $4.3B and an enterprise value of $3.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$197.2M.

  • Diluted earnings per share, trailing twelve months: $−1.85.

  • Free cash flow in the twelve months to 30 June 2026: −$158.8M.

  • Shares outstanding: 107.8M.

  • Trailing P/E: −24.1×; forward P/E: −22.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Edgewise Therapeutics, Inc. employs 127 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Oct 2026

Data provided by Twelve Data

Peers

EWTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EWTXEdgewise Therapeutics, Inc.$4.3B56
DNTHDianthus Therapeutics, Inc.$4.2B61
RLAYRelay Therapeutics, Inc.$3.9B71
ARQTArcutis Biotherapeutics, Inc.$3.9B81
DFTXDefinium Therapeutics, Inc.$4.6B43
ABCLAbCellera Biologics, Inc.$3.8B71
TNGXTango Therapeutics, Inc.$3.8B42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Edgewise Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EWTX news & analysis

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

PRNewsWire · 8 Oct 2026positive

Edgewise Therapeutics announced that the first patient has been dosed in EQUINOX-HFpEF, a Phase 2 trial of EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%. The company said the trial design and Phase 1 first-in-human data are to be presented at HFSA 2026.

Why it matters — The dosing marks the start of a Phase 2 evaluation of EDG-15400 in the specified HFpEF population.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

PRNewsWire · 1 Oct 2026neutral

Edgewise Therapeutics announced that on September 30, 2026, it granted inducement stock options covering 7,500 shares and restricted stock units covering 3,751 shares of common stock to three new non-executive employees, issued under its 2024 Inducement Equity Incentive Plan as permitted by Nasdaq listing rules.

Why it matters — The inducement grants offer EWTX watchers insight into the company's approach to equity compensation for newly hired employees under its inducement plan.

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript

Seeking Alpha · 22 Sept 2026neutral

Edgewise Therapeutics presented a discussion transcript covering the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500. The item outlines the company's explanation of how the investigational product is designed to work.

Why it matters — A watcher of Edgewise Therapeutics would care because clarity on EDG-7500's mechanism of action speaks to the science behind one of the company's key development programs.

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

PRNewsWire · 22 Sept 2026positive

Edgewise Therapeutics announced the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain. Preclinical models showed the drug improves cardiac relaxation while preserving systolic function and cardiac reserve, and the company hosted a webcast to discuss these findings.

Why it matters — This provides a clearer scientific basis for EDG-7500's potential in cardiac disease, which EWTX watchers would see as a meaningful advancement in the company's pipeline.

Biotech Options Buzz: UTHR, NMRA, EWTX

Schaeffers Research · 18 Sept 2026neutral

Edgewise Therapeutics (NASDAQ: EWTX) appeared on Schaeffers Research's list of biotech stocks drawing outsized unusual options volume, alongside United Therapeutics and Neumora Therapeutics. The report notes heightened options activity for these three biotech names.

Why it matters — An EWTX watcher would care because increased options activity can signal rising investor attention and changing market sentiment toward the stock.

FAQ

Frequently asked questions about EWTX stock

What is the EWTX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Edgewise Therapeutics, Inc. have a median 12-month price target of $53, with estimates ranging from $36 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EWTX stock a buy right now?

Of the 14 analysts covering Edgewise Therapeutics, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edgewise Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EWTX?

As at 24 Oct 2026, Edgewise Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will EWTX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +34.8% from the last close, and Ticker Nerd's factor model ranks Edgewise Therapeutics, Inc. 56 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EWTX stock forecast for 2030?

No analyst covering Edgewise Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $66 over the next 12 months.

How has EWTX stock performed over the past year?

Edgewise Therapeutics, Inc. returned +160.3% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edgewise Therapeutics, Inc. do?

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders.

What is the latest news on EWTX?

The most recent item we track (PRNewsWire, 8 Oct 2026): "Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400". Edgewise Therapeutics announced that the first patient has been dosed in EQUINOX-HFpEF, a Phase 2 trial of EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%. The company said the trial design and Phase 1 first-in-human data are to be presented at HFSA 2026.

Company

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for severe muscle and cardiac disorders. The company’s current portfolio centers on precision medicine programs designed to address rare neuromuscular diseases and inherited heart conditions, with a platform built around small-molecule approaches that target key muscle proteins and pathways. Its work spans muscular dystrophy and hypertrophic cardiomyopathy research, as well as other disorders where abnormal muscle function plays a central role. Edgewise Therapeutics Inc. operates as a clinical-stage developer of medicines aimed at improving how muscle diseases are treated in specialized medical settings, supporting both neuromuscular and cardiovascular care.

CEO Dr. Kevin Koch Ph.D. · 127 employees · United States · https://edgewisetx.com